Login
Registrati
Reimposta password
Pubblica & Distribuisci
Soluzioni Editoriali
Soluzioni di Distribuzione
Temi
Architettura e design
Arti
Business e Economia
Chimica
Chimica industriale
Farmacia
Filosofia
Fisica
Geoscienze
Ingegneria
Interesse generale
Legge
Letteratura
Linguistica e semiotica
Matematica
Medicina
Musica
Scienze bibliotecarie e dell'informazione, studi library
Scienze dei materiali
Scienze della vita
Scienze informatiche
Scienze sociali
Sport e tempo libero
Storia
Studi classici e del Vicino Oriente antico
Studi culturali
Studi ebraici
Teologia e religione
Pubblicazioni
Riviste
Libri
Atti
Editori
Blog
Contatti
Cerca
EUR
USD
GBP
Italiano
English
Deutsch
Polski
Español
Français
Italiano
Carrello
Home
Riviste
PRILOZI
Volume 44 (2023): Numero 3 (December 2023)
Accesso libero
Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms– Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience
Marija Popova-Labachevska
Marija Popova-Labachevska
,
Milche Cvetanoski
Milche Cvetanoski
,
Nevenka Ridova
Nevenka Ridova
,
Sanja Trajkova
Sanja Trajkova
,
Simona Stojanovska-Jakimovska
Simona Stojanovska-Jakimovska
,
Tara Mojsovska
Tara Mojsovska
,
Zlate Stojanoski
Zlate Stojanoski
,
Aleksandra Pivkova-Veljanovska
Aleksandra Pivkova-Veljanovska
e
Irina Panovska-Stavridis
Irina Panovska-Stavridis
| 18 dic 2023
PRILOZI
Volume 44 (2023): Numero 3 (December 2023)
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Sommario
Bibliografia
Autori
Articoli in questo Numero
Anteprima
PDF
Cita
CONDIVIDI
Pubblicato online:
18 dic 2023
Pagine:
57 - 62
DOI:
https://doi.org/10.2478/prilozi-2023-0047
Parole chiave
Essential Thrombocythemia
,
Polycythemia Vera
,
Primary Myelofibrosis
,
myeloproliferative neoplasms
,
ropeginterferon alfa-2b
© 2023 Marija Popova-Labachevska et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Marija Popova-Labachevska
University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje
RN Macedonia
Milche Cvetanoski
University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje
RN Macedonia
Nevenka Ridova
University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje
RN Macedonia
Sanja Trajkova
University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje
RN Macedonia
Simona Stojanovska-Jakimovska
University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje
RN Macedonia
Tara Mojsovska
University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje
RN Macedonia
Zlate Stojanoski
University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje
RN Macedonia
Aleksandra Pivkova-Veljanovska
University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje
RN Macedonia
Irina Panovska-Stavridis
University clinic of hematology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje
RN Macedonia